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Abstract
Introduction: This is the case of a rare and regional disease not often considered in the
immunocompromised patient presenting with a chief complaint of fever.
Case presentation: A 37-year-old immunocompromised Indian woman presented with a chief
complaint of fever, in the absence of localizing signs and symptoms, from an area endemic to Babesia
microti.
Conclusions: Our patient’s case is instructive in that Babesiosis and other arthropod born illnesses
should be considered in immunocompromised patients presenting with fever in the absence of
localizing signs or symptoms. This is especially true when he or she presents from an area with
known endemic disease. While the management of fever in immunocompromised patients is largely
standardized, considering Babesiosis from the beginning may prompt early investigation of a blood
smear, which has the potential to alert the emergency department physician to Babesiosis. In
addition, considering the disease from the outset has the potential to accelerate administration of the
appropriate antimicrobial therapy and thus prevent unnecessary morbidity and possible mortality.
Introduction
The differential diagnosis of fever in the immunocom-
promised patient is extensive, often including exotic and
rare infections. Diagnosis is complicated by the fact that
localizing signs and symptoms of infection may be
absent in this population. Fever in the immunocompro-
mised patient is most often a result of a community
acquired bacterial infection [2]. In addition to infection
caused by the more common community acquired
bacteria, opportunistic bacterial disease, along with
fungal, viral, and arthropod disease, as well as important
non-infectious etiologies, need to be considered [12].
In this paper, we present a case of a rare and regional
disease not often considered in the immunocom-
promised patient presenting with a chief complaint of
fever.
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A 37-year-old Indian woman presented to our university
based, academic emergency department, with a chief
complaint of fever of one-week duration. The patient
reported the fever was persistent and fluctuated between
102 and 103 degrees Fahrenheit. The elevated tempera-
tures were associated with shaking chills and diffuse
myalgias. Review of systems was otherwise unremarkable.
She denied any recent change in her appetite or weight.
The patient had a past medical history significant for
Systemic Lupus Erythematosis (SLE) that was diagnosed at
age 16. She received a cadaveric renal transplant ten years
prior to admission secondary to Lupus nephropathy. Over
the past year, the patient had suffered from chronic
rejection and was on the renal transplant list for a second
time. Additional past medical history includes hyperten-
sion, chronic Molluscum contagiosum on the lower extre-
mities, thyroid cancer status post total thyroidectomy, and
renal cell carcinoma status post right native nephrectomy.
Medications included tacrolimus 2 milligrams twice daily,
prednisone 5 milligrams daily, darbepoetin alfa 60
milligrams subcutaneously weekly, atenolol 25 milligrams
daily, amlodipine 5 milligrams daily, calcitriol 0.25
micrograms daily, levothyroxine 100 micrograms daily,
iron supplementation, and a daily multivitamin. Myco-
phenolate mofetil was recently stopped secondary to
epistaxis and gingival bleeding. The patient denied any
known drug allergies and was not taking any over the
counter medications.
The patient denied any recent travel history but did report
spending fourteen days in Nicaragua approximately nine
months prior to presentation. While in Nicaragua, the
patient recalled a transient diarrheal illness that resolved
without incident. The patient denied a history of smoking,
alcohol use, illegal drug use, or high-risk sexual behavior.
On physical examination, the patient was awake, alert, and
oriented to person, place, and time and in no acute
distress. The patient’s vital signs were as follows: blood
pressure 112/81, heart rate 115, respiratory rate 16, oral
temperature 101.6 degrees Fahrenheit, oxygen saturation
on room air 97 percent. The remainder of the patient’s
physical examination was unremarkable except for the
skin, which was warm, dry, and with numerous 2-5
millimeter pearly, flesh-colored, umbilicated papules on
the lower extremities consistent with Molluscum
contagiosum.
Initial laboratory studies (Table 1) were significant for a
relative monocytosis, normochromic normocytic anemia,
increased lactate dehydrogenase with normal Coombs
test, thrombocytopenia, high indirect bilirubin,
hyponatremia, metabolic acidemia, and renal failure.
The patient reported her creatinine was recently measured
to be approximately 2.4. It was 3.7 in the emergency
department at presentation. A urine analysis was per-
formed and found to contain 1+ blood; however,
microscopic analysis failed to reveal any erythrocytes.
Figure 1. Blood Smear from patient showing
intra-erythocyte ring forms.
Table 1. Initial Laboratory Results
Leukocyte Count 4.7 x 10
3/mm
3
Hemoglobin 8.1 g/dl
Hematocrit 24 %
Platelet Count 76 × 10
3/mm
3
Mean Corpuscular Volume 82.3 μm
3
Mean Corpuscular Hemoglobin 27.7 pg/cell
Mean Corpuscular Hemoglobin
Concentration
33.7 g/dl
Red Cell Distribution Width 14.8 %
Neutrophils 59 %
Band Forms 0 %
Lymphocytes 14 %
Monocytes 26 %
Eosinophils 1 %
Basophils 0 %
Sodium 130 mEq/liter
Potassium 4.2 mEq/liter
Chloride 101 mEq/liter
Total Carbon Dioxide 19 mEq/liter
Urea Nitrogen 78 mg/dl
Creatinine 3.7 mg/dl
Glucose 120 mg/dl
Total Protein 6.2 g/dl
Albumin 3.1 g/dl
Total Bilirubin 1.2 mg/dl
Direct Bilirubin 0.3 mg/dl
Alkaline Phosphatase 53 U/liter
Aspartate Aminotransferase 38 U/liter
Alanine Aminotransferase 32 U/liter
Blood Culture 1 neg
Blood Culture 2 neg
Urine Culture neg
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any acute disease process. A blood smear was obtained
(Figure 1). Numerous ring trophozites measuring approxi-
mately 2.0 microns were seen and estimated to involve 3.8
percent of the erythrocytes. The infected erythrocytes
appeared the same size as the surrounding, non-infected
cells. No other inclusions, with the exception of the
pyroplasms, were seen in the erythrocytes. A rapid malaria
antigen test was performed and found to be negative.
At this point, the patient was admitted with a presumptive
diagnosis of Babesiosis. The patient was started on
azithromycin 250 milligrams daily, doxycycline 100
milligrams twice daily, and atovaquone 750 milligrams
twice daily. On hospital day two, additional data was
obtained about the patient’s hematologic status. The
patient was found to have a reticulocyte count of 1.32
(an inadequate bone marrow response most likely
secondary to chronic renal failure), a haptoglobin level
less than7, anda falling hemoglobin level. Inthe settingof
increased red cell destruction and decreased red cell
production, the patient was transfused two units of packed
red blood cells. The patient responded well to the
transfusions and her hemoglobin subsequently stabilized
while her lactate dehydrogenase and haptoglobin
improved only marginally.
While the patient’s hemoglobin initially dropped, the
patient’s renal function steadily improved with treatment
of her underlyinginfection. Bythe endof thepatient’sone-
week hospital stay, her creatinine had returned to baseline.
In addition, her bilirubin, electrolytes, white blood cell
count, and platelet count improved over the week.
The diagnosis of Babesiosis was eventually confirmed by
polymerase chain reaction (PCR) performed by Focus
Diagnostics Incorporated in Cypress, California. In addi-
tion, a diagnosis of Lyme disease was presumed secondary
to elevated Lyme titers and high rate of concurrent
infection of Babesiosis with Lyme disease. Our patient
did extremely well and was discharged home with no
residual symptoms.
Discussion
Babesiosis was first discovered at the end of the 19th
century as a cause of “red water fever” in cattle [1]. Later,
Babesia became the first recognized arthropod-borne
pathogen of vertebrates [5]. Today, it is a known zoonotic
cause of human febrile disease. The etiologic agent of
Babesiosis in North America is most often Babesia microti,a
protozoan parasite of small mammals. Babesia divergens is
found as the etiologic agent of Babesiosis in Europe.
Babesia is transmitted by the Ixodes scapularis,m o r e
commonly known as the deer tick. This same tick is also
responsible for the transmission of Borrelia burgdorferi, the
etiologic agent of Lyme disease, and Anaplasma phagocyto-
phila, the etiologic agent of human granulocytic anaplas-
mosis. Humans most often acquire the disease through the
bite of the deer tick and infrequently through contami-
nated blood transfusions [3].
According to the Centers for Disease Control, Babesia is
endemic to the Northeastern United States, more specifi-
cally New York, Massachusetts, Connecticut, and Rhode
Island. There is also a considerable focus of disease in
Wisconsin and Minnesota. In 2003, New Jersey was added
to the list of states Babesia calls home. All reported and
confirmed cases of Babesiosis in New Jersey have occurred
in the central portion of the state with most being reported
in Burlington and Ocean Counties [4]. Peak transmission
occurs from May to September, with July being the most
common month of infection. Children and adults are
affected equally; however, adults tend to have a greater
proportion of symptomatic infections [5].
Clinically, Babesiosis most often presents in a flu-like
manner with fever, chills, diaphoresis, malaise, myalgias,
and arthralgias. Patients have also reported headache, neck
stiffness, sore throat, cough, shortness of breath, anorexia,
nausea, vomiting, and hepatosplenomegaly. Patients can
alsobecompletelyasymptomatic.InastudybyHatcheretal
of thirty-four cases of Babesiosis in an endemic area of New
York, it was found that patients presented on average 15.4
days after the onset of symptoms. In addition, only thirty-
two percent of patients were able to recount a tick bite [3].
Objectively, patients often present with hemolytic anemia
as evidenced by an elevated indirect bilirubin, elevated
lactate dehydrogenase, and depleted haptoglobin levels. If
hemolysis is present, urine analysis often reveals hemo-
globinuria and proteinuria without the concomitant
presence of microscopic red cells. Leucopenia and
thrombocytopenia may also be present secondary to a
Tumor necrosis factor (TNF)-mediated immune response.
Patients may also have elevated liver enzymes including
aspartate aminotransferase, alanine aminotransferase, and
alkaline phosphatase [5].
Babesiosis can often be clinically confused with Ehrlichio-
sis, Lyme disease, Malaria, Rocky Mountain Spotted Fever
(RMSF), and Typhoid. When the history and physical are
inadequate to make a diagnosis, as in the absence of a
telltale “bulls eye” or centripetal rash, distinguishing the
aforementioned diseases can start with an investigation for
the presence or absence of hemolytic anemia as outlined
above. Doing so would reliably rule out Ehrlichiosis, Lyme
disease, RMSF, and Typhoid, as hemolytic anemia is
uncharacteristic of these diseases. However, it is important
to note that concurrent infection of Babesiosis with Lyme
disease and Ehrlichiosis has been reported [8].
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from Babesia, the etiologic agent of Babesiosis, can be
achieved in a number of ways. The simplest is through
giemsa-stained thin blood smears revealing intra-erythro-
cyte ring forms, also known as pyriform inclusions, with
light blue cytoplasm. A smear of Babesia infected
erythrocytes is characteristically very similar to that of
erythrocytes infected with Plasmodium; however, they can
be differentiated by the greater degree of pleomorphisms
as well as the presence of the pathognomonic finding of
trophozites in the form of Maltese crosses in Babesia
smears. Diagnosis is confirmed through serologic testing
or PCR. PCR targeting of the 18S rDNA portion of the
genome is more sensitive than, and equally specific as,
serologic testing in the detection of acute Babesia spp.
Infections with as few as three parasites in 100 microliters
of blood can yield a positive result with PCR [5,6].
Microscopically, Babesia invades erythrocytes and causes
damage through parasite directed alterations of the
erythrocyte membrane [9]. These changes cause erythro-
cytes to adhere to the endothelium of the microvasculature
resulting in excessive pro-inflammatory cytokine release
and tissue hypoxia [5]. In addition, the finding of anemia
is a result of the lysis of erythrocytes [10]. The severity of
disease is proportional to the parasite load with complica-
tions most commonly occurring in those individuals with
a parasitemia level greater than 10.0 percent or hemoglo-
bin less than 10.0 grams/deciliter on admission [3].
Complications of Babesiosis include acute respiratory
failure (20.6%), disseminated intravascular coagulation
(17.6%), non-cardiogenic pulmonary edema (11.8%),
and renal failure (5.9%) [3].
Immunocompromised hosts are more susceptible to
Babesiosis than the immunocompetent population.
More specifically, those patients treated with prednisone
and tacrolimus are at risk of symptomatic infection
because these drugs suppress T-cell activation and
calcineuron/interleukin-2 production needed to fight an
intracellular pathogen. Because of this decreased immune
response, an immunocompromised patient is more likely
to have a high peak parasitemia level and thus more likely
to suffer from severe disease and complications [3,7,9].
The rate of mortality has been estimated to be approxi-
mately five percent in patients with clinically evident
disease and thus treatment is indicated for all patients
presenting for medical care. Prior to 2000, the treatment of
Babesiosis had classically entailed a combination of
quinine and clindamycin. In 2000, Krause et al showed
that the combination of atovaquone and azithromycin
was as efficacious as the standard treatment and consider-
ably more tolerable. Patients with severe disease and those
at risk for complications may also require exchange
transfusion which may be curative in those situations.
Interestingly, Babesia infections in immunocompromised
individuals can persist despite treatment. These patients
are more likely to relapse or continue to remain subclinical
hosts for the parasite. In 2008, Krause et al found that
immunocompromised patients required treatment for at
least two weeks after the blood smear no longer shows
trophozites in erythrocytes in order for a cure to have been
achieved [9-11].
Conclusions
Our patient’s case is instructive in that Babesiosis and
other arthropod born illnesses should be considered in
immunocompromised patients presenting with fever in
the absence of localizing signs or symptoms. This is
especially true when he or she presents from an area with
endemic disease. While the management of fever in
immunocompromised patients is largely standardized
from an emergency department perspective, considering
Babesiosis from the beginning may prompt early investi-
gation of a blood smear, which has the potential to alert
the emergency department physician to Babesiosis. In
addition, considering the disease from the outset has the
potential to accelerate administration of the appropriate
antimicrobial therapy and thus prevent unnecessary
morbidity and possible mortality.
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